CALL FOR ABSTRACTS: 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia

 

2nd Translational Research Conference
Acute Lymphoblastic Leukaemia

 

Save the dates: May 07-09, 2021
E-CONFERENCE - #ESHALL2021
FREE REGISTRATION

  Chairs: Jan Cools, Hervé Dombret, Adele Fielding, Mark Litzow

---

CALL FOR ABSTRACTS!
DEADLINE: MARCH 3rd, 2021
Abstracts are eligible to be selected
for an oral or a poster presentation.

---

ABOUT THE E-CONFERENCE:

In view of continuing COVID-19 related challenges, this 2nd Translational Research Conference on Acute Lymphoblastic Leukaemia will be held as a virtual event.

REGISTRATION IS OFFERED FREE OF CHARGE as a gesture of solidarity during these difficult times.

The E-Conference will welcome an outstanding faculty of global authorities for a scientific programme that is designed to integrate leading-edge basic, clinical and therapeutic advances, and new perspectives.

Major recent advances in the knowledge of the biological underpinning of acute lymphoblastic leukaemia (ALL) include the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, the identification of new potentially druggable disease subsets and the discovery of predisposing, preleukaemic events.

At the same time, the clinical management of the disease has improved in both children and adults thanks to the routine monitoring of measurable residual disease (MRD), the administration of intensified risk-adapted chemotherapy, the introduction of targeted therapies and antibodies, and the remarkable efficacy of antibody-drug conjugates (ADCs), bi-specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.

This intense research activity has led to major improvements in patient outcome, while also providing important proofs of concept for the treatment of cancer in general. It has also made ALL a fascinating disease to study.

Submitted abstracts will be considered for presentation as Brief Oral Communications or Posters. Opportunities for exchange with the faculty include face-to-face live discussions during closed Meet the Expert sessions and during the plenary Mentored Poster Walks.

A strong emphasis will be placed on scientific discussion and debate throughout the meeting.

LEARNING OBJECTIVES:
Upon completion of this CME activity, participants should have:
- improved their understanding of how to optimally diagnose and classify ALL by combining modern diagnostic algorithms and early MRD monitoring for the rapid delivery of the right treatment to the right patient;
- an overview of conventional therapeutic options, with a focus on the role of allogeneic haemopoietic stem cell transplantation;
- learned how to optimize the management of individual patients on the basis of individual drug metabolism, tolerance and toxicity;
- improved their knowledge of new, emerging targeted or immunological treatments and understand how they may be combined or how they could eventually replace current conventional treatment options.

 

SCIENTIFIC TOPICS:
- Biology of B-cell precursor ALL
- Biology of T-cell ALL
- Minimal residual disease monitoring
- Individualized management of ALL
- New advances in ALL
- Car T-cells & allogeneic HSCT
- Frontline incorporation of BiTEs and ADCs
- T-cell ALL and lymphoblastic lymphoma
- Ph and PH-like ALL.

STAY TUNED REGISTRATION OPENING SOON!

---

TO ACCESS THE UPDATED PROGRAMME CLICK HERE

TO MEET THE FACULTY CLICK HERE

MORE INFORMATION